journal
MENU ▼
Read by QxMD icon Read
search

Melanoma Research

journal
https://www.readbyqxmd.com/read/28885396/a-prospective-multicenter-cohort-study-of-cutaneous-melanoma-clinical-staging-and-potential-associations-with-hif-1%C3%AE-and-vegf-expressions
#1
Miguel Ángel Martínez-García, Erica Riveiro-Falkenbach, José L Rodríguez-Peralto, Eduardo Nagore, Antonio Martorell-Calatayud, Francisco Campos-Rodríguez, Ramón Farré, Luis Hernández Blasco, Jose Bañuls Roca, Eusebi Chiner Vives, Alicia Sánchez-de-la-Torre, Jorge Abad Capa, Josep Maria Montserrat, Isaac Almendros, Amalia Pérez-Gil, Valentin Cabriada Nuño, Irene Cano-Pumarega, Jaime Corral Peñafiel, Trinidad Diaz Cambriles, Olga Mediano, Joan Dalmau Arias, David Gozal
Melanoma is a highly prevalent cancer that is associated with substantial mortality. Although clinical staging procedures can serve as relatively robust prognostic indicators, we aimed to determine whether assessments of the abundance of hypoxia inducible factor-1α (HIF-1α) or vascular endothelial growth factor (VEGF) in postexcisional melanoma tumor tissues may enable more accurate determination of tumor aggressiveness. We carried out a multicenter prospective study, in which we systematically evaluated 376 consecutive patients diagnosed with melanoma, and performed histochemical assessments for both HIF-1α and VEGF immunoreactivity in the tumor biopsies...
September 6, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28877050/metformin-oxidative-and-proliferative-parameters-in-vitro-and-in-vivo-models-of-murine-melanoma
#2
Fernando P de Souza Neto, Sara S Bernardes, Poliana C Marinello, Gabriella P Melo, Rodrigo C Luiz, Rubens Cecchini, Alessandra L Cecchini
Cutaneous melanoma is one of the most lethal cancers because of its increased rate of metastasis and resistance to available therapeutic options. Early studies indicate that metformin has beneficial effects on some types of cancer, including melanoma. To clarify knowledge of the mechanism of action of metformin on this disease, two treatment-based approaches are presented using metformin on melanoma progression: an in-vitro and an in-vivo model. The in-vitro assay was performed for two experimental treatment periods (24 and 48 h) at different metformin concentrations...
September 4, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28872489/a-case-of-pure-red-cell-aplasia-during-nivolumab-therapy-for-cardiac-metastatic-melanoma
#3
Akihiko Yuki, Tatsuya Takenouchi, Sumiko Takatsuka, Takuro Ishiguro
Nivolumab is an antibody against programmed cell death 1 and functions as an immune checkpoint inhibitor for various malignancies, including unresectable melanomas. Nivolumab causes several immune-related adverse events, which typically include skin rash, pneumonitis, thyroid dysfunction, hepatitis, and colitis; in rare cases, anemia may be present. There are several reports of autoimmune hemolytic anemia that has developed in response to nivolumab; however, there are few reports of pure red cell aplasia (PRCA)...
September 1, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28872488/acute-motor-and-sensory-axonal-neuropathy-related-to-treatment-with-mek-inhibitors-in-a-patient-with-advanced-melanoma
#4
Tarek Taha, Tzahala Tzuk-Shina, Itay Forschner, Gil Bar-Sela
Approximately one-half of advanced cutaneous melanomas have a V600 mutation in the BRAF gene that activates the mitogen-activated protein kinase pathway. The combination of BRAF plus MEK inhibitors is one of the most effective treatments for these patients. Severe neurological toxicities have been reported in the literature. However, these toxicities are very rare. Here, we present one patient with acute motor and sensory axonal neuropathy, which is a subtype of Guillain-Barre syndrome, secondary to treatment with MEK inhibitors...
September 1, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28858076/putative-genomic-characteristics-of-braf-v600k-versus-v600e-cutaneous-melanoma
#5
Yuanyuan Li, David M Umbach, Leping Li
Approximately 50% of all cutaneous melanomas harbor activating BRAF V600 mutations; among, these 10-30% carry the V600K mutation. Clinically, patients with V600K tumors experience distant metastases sooner and have an increased risk of relapse and shorter survival than patients with V600E tumors. Despite the clinical and other histopathological differences between these BRAF tumor subtypes, little is known about them at the genomic level. Herein, we systematically compared BRAF V600E and V600K skin cutaneous melanoma (SKCM) samples from the Cancer Genome Atlas (TCGA) for differential protein, gene, and microRNA expression genome-wide using the Mann-Whitney U-test...
August 28, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28825947/a-unique-gene-expression-signature-is-significantly-differentially-expressed-in-tumor-positive-or-tumor-negative-sentinel-lymph-nodes-in-patients-with-melanoma
#6
Ahmad A Tarhini, Theofanis Floros, Hui-Min Lin, Yan Lin, Zahra Rahman, Madeeha Ashraf, Priyanka Vallabhaneni, Cindy Sander, Uma N M Rao, Monica Panelli, William F LaFramboise, John M Kirkwood
The purpose of this study was to learn whether molecular characterization through gene expression profiling of node-positive and node-negative sentinel lymph nodes (SLNs) in patients with clinical stage I and II melanoma may improve the understanding of mechanisms of metastasis and identify gene signatures for SLNs/SLNs that correlate with diagnosis or clinical outcome. Gene expression profiling was performed on SLN biopsies of 48 (24 SLN and 24 SLN) patients (T3a/b-T4a/b) who underwent staging of SLNs using transcriptome profiling analysis on 5 μm sections of fresh SLNs...
August 18, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28817446/bevacizumab-as-an-effective-treatment-for-radiation-necrosis-after-radiotherapy-for-melanoma-brain-metastases
#7
Isabella C Glitza, Nandita Guha-Thakurta, Neil M D'Souza, Rodabe N Amaria, Susan L McGovern, Ganesh Rao, Jing Li
Radiation necrosis (RN) is a potential late complication of radiotherapy for intracranial malignancy, which is often associated with significant neurological morbidity. Prolonged treatment with high-dose corticosteroids or surgical resection has been the standard care for RN, but protracted steroid use can lead to significant side effects and surgical resection is not always feasible. The antivascular endothelial growth factor monoclonal antibody bevacizumab induces clinical and radiographic improvements in RN, with overall good tolerance...
August 16, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28800030/response-to-targeted-therapy-in-two-patients-with-metastatic-melanoma-carrying-rare-braf-exon-15-mutations-a598_t599insv-and-v600_k601delinse
#8
Aljosja Rogiers, Sara Vander Borght, Krizia Tuand, Pascal Wolter, Marguerite Stas, Veerle Boecxstaens, Marjan Garmyn, Joost J van den Oord, Peter Vandenberghe, Oliver Bechter
Concurrent BRAF-MEK inhibition improves clinical outcomes in patients with advanced BRAF V600E/K-mutant melanoma. There is currently less evidence for the efficacy of this treatment in patients with rare BRAF non-V600E/K genotypes. We report on two patients with rare BRAF exon 15 mutations - BRAF A598_T599insV and V600_K601delinsE - obtaining clinical benefit and a radiological response to inhibitors directed against the mitogen-activated protein kinase pathway. This highlights the importance of using tests that detect both V600E/K and non-V600E/K BRAF mutations to keep open the possibility of treatment with targeted therapy in patients with uncommon, yet potentially actionable, BRAF exon 15 mutations...
August 10, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28800029/the-role-of-depression-and-personality-traits-in-patients-with-melanoma-a-south-european-study
#9
Helen J Gogas, Maria A Karalexi, Nick Dessypris, Antonios G Antoniadis, Fotis Papadopoulos, Eleni T Petridou
We explored the potential association of depression history and personality, evaluated through a robust questionnaire tool, namely the Eysenck Personality Scale, with disease risk and progression among Greek patients. A total of 106 melanoma patients and their 1 : 1 sex-matched controls were interviewed on the basis of a questionnaire comprising phenotypic, sociodemographic, lifestyle and medical history variables, as well as information on history of lifetime major depression. The Eysenck Personality Questionnaire, measuring the four personality dimensions (extraversion, neuroticism, psychoticism, lie), was thereafter completed...
August 10, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28800028/current-status-and-future-direction-in-the-management-of-malignant-melanoma
#10
Patrick Gladfelter, Noureldien H E Darwish, Shaker A Mousa
The incidence of malignant melanoma is increasing rapidly on a global scale. Although some types of melanoma, for example primary cutaneous melanoma, can be managed by surgery, metastatic melanoma cannot and it has a high mortality rate. Both oncogene and immune-targeted strategies have shown marked efficacy in some patients, but their effect on overall survival is still variable. Therefore, newer therapeutic approaches are needed. Fortunately, new advances in molecular medicine have led to an understanding of an individual patient's cancer at the genomic level...
August 10, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28800027/economic-burden-of-advanced-melanoma-in-france-germany-and-the-uk-a-retrospective-observational-study-melanoma-burden-of-illness-study
#11
Florent Grange, Peter Mohr, Mark Harries, Rainer Ehness, Laure Benjamin, Obukohwo Siakpere, Janina Barth, Ceilidh Stapelkamp, Sylvie Pfersch, Lori D McLeod, James A Kaye, Sorrel Wolowacz, Ilias Kontoudis
The aim of this study was to estimate the cost-of-illness associated with completely resected stage IIIB/IIIC melanoma with macroscopic lymph node involvement, overall and by disease phase, in France, Germany and the UK. This retrospective observational study included patients aged older than or equal to 18 years first diagnosed with stage IIIB/IIIC cutaneous melanoma between 1 January 2009 and 31 December 2011. Data were obtained from medical records and a patient survey. Direct costs, indirect costs and patient out-of-pocket expenses were estimated in euros (&OV0556;) (and British pounds, £) by collecting resource use and multiplying by country-specific unit costs...
August 10, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28727675/type-1-diabetes-mellitus-caused-by-treatment-with-low-dose-interferon-%C3%AE-in-a-melanoma-patient
#12
Daniel Sossau, Lukas Kofler, Thomas Eigentler
Interferon-α (INF-α) is used as an adjuvant treatment for high-risk cutaneous melanoma. It has a large variety of potentially severe and irreversible side effects and can contribute toward the development of autoimmune disease. We report a case of a 59-year-old woman who developed type 1 diabetes following the use of low-dose IFN-α for the adjuvant treatment of stage IIB melanoma. Fifteen months after initiating IFN-α, she presented with blood glucose of 1126 mg/dl, hyponatremia, and microalbuminuria...
July 19, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28723726/impact-of-socioeconomic-status-and-district-of-residence-on-cutaneous-malignant-melanoma-prognosis-a-survival-study-on-incident-cases-between-1991-and-2011-in-the-province-of-ferrara-northern-italy
#13
Alessandro Borghi, Monica Corazza, Annarosa Virgili, Anna G Lambertini, Nicola Caranci, Barbara Pacelli, Paolo Carcoforo, Stefano Ferretti
The aim of this study was to analyse the impact of socioeconomic status (SES) on the prognosis of patients with invasive malignant melanoma (MM) incident from 1991 to 2011 in the province of Ferrara, northern Italy. A total of 750 patients provided by the Area Vasta Emilia Centrale Cancer Registry were included in this retrospective cohort study. Prognosis was analysed in terms of overall survival and specific survival. The study determinants were the patients' SES and district of residence. The confounding effect of sex, age, period and TNM stage at diagnosis was evaluated...
July 18, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28723725/meningeal-melanomatosis-following-discontinuation-of-dabrafenib-implications-for-the-maintenance-of-long-term-complete-remission
#14
Victoria Grätz, Nadine Lüttmann, Ozan Haase, Ewan A Langan, André Kemmling, Detlef Zillikens, Patrick Terheyden
A subset of 10-20% of patients under continuous BRAF inhibitor monotherapy achieve long-term progression-free and overall survival. Definitive criteria for the safe cessation of BRAF inhibitor monotherapy in treatment-responsive melanoma patients are lacking. We report a patient who remained in complete remission (CR) for 5 years under dabrafenib. The treatment was withdrawn because of concerns about cardiac toxicity. Four months thereafter the patient developed neurological symptoms, including diplopia and bilateral visual loss...
July 18, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28692456/focal-necrotizing-myopathy-with-dropped-head-syndrome-induced-by-cobimetinib-in-metastatic-melanoma
#15
Marie-Léa Gauci, Pauline Laly, Leonard-Louis Sarah, Anthony Behin, Jérémy Gottlieb, Isabelle Madelaine-Chambrin, Barouyr Baroudjian, Laetitia Da-Meda, Samia Mourah, Maxime Battistella, Nicole Basset Seguin, Martine Bagot, Cécile Pages, Laetitia Vercellino, Thierry Maisonobe, Céleste Lebbé
Therapeutic advances derived from targeted therapy and immune checkpoint inhibitors can improve melanoma prognosis. Since 2015, cobimetinib has been approved in combination with vemurafenib in the first-line treatment for BRAF-mutated melanoma. For NRAS-mutated melanomas, MEK inhibition seems to be a therapeutic target, and association with checkpoint inhibitor provides a further therapeutic perspective. Infraclinical creatine phosphokinase (CPK) elevation is an MEK inhibitor side effect. We describe a case of focal necrotizing myopathy with 'dropped-head syndrome' induced by cobimetinib, 1 month after its introduction...
July 7, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28858175/fulminant-type-1-diabetes-after-adjuvant-ipilimumab-therapy-in-cutaneous-melanoma
#16
Aikaterini Tsiogka, Gerhard L Jansky, Johann W Bauer, Peter Koelblinger
No abstract text is available yet for this article.
October 2017: Melanoma Research
https://www.readbyqxmd.com/read/28858075/concurrent-radiotherapy-for-patients-with-metastatic-melanoma-and-receiving-anti-programmed-death-1-therapy-a-safe-and-effective-combination
#17
Amélie Aboudaram, Anouchka Modesto, Léonor Chaltiel, Carlos Gomez-Roca, Serge Boulinguez, Vincent Sibaud, Jean-Pierre Delord, Ciprian Chira, Martine Delannes, Elizabeth Moyal, Nicolas Meyer
A combination of immune-checkpoint inhibitors and radiation therapy (RT) represents a promising therapeutic strategy in part mediated by the abscopal effect, but clinical experience related to this combination remains scarce. Clinical data and patterns of treatment were retrospectively collected from all consecutive patients with metastatic melanoma and receiving programmed-death 1 (PD-1) immune-checkpoint inhibitors. Survival data, best overall response, and acute and delayed toxicities (graded according to Common Terminology Criteria for Adverse Events, v 4...
October 2017: Melanoma Research
https://www.readbyqxmd.com/read/28817445/the-safety-of-pembrolizumab-in-metastatic-melanoma-and-rheumatoid-arthritis
#18
Akshjot Puri, Jade Homsi
Immunotherapy has been in use for the treatment of melanoma since a very long time, but only recently have the cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody ipilimumab and programmed cell death-1 inhibitors such as nivolimumab and pembrolizumab been shown to induce marked improvements in survival in patients with metastatic melanoma. An important concern arises in terms of the safety of the use of these agents in patients with autoimmune diseases, solid organ transplant recipients on immunosuppression, patients with a history of previous hepatitis B or C, and patients with HIV infections as these patients were excluded from pivotal immunotherapy studies...
October 2017: Melanoma Research
https://www.readbyqxmd.com/read/28800032/malignant-melanoma-incidence-trends-in-a-mediterranean-population-following-socioeconomic-transition-and-war-results-of-age-period-cohort-analysis-in-croatia-1989-2013
#19
Jelena Barbaric, Mathieu Laversanne, Ariana Znaor
The aim of this study was to analyse trends of malignant melanoma incidence in Croatia for men and women of different age groups by birth cohorts and time periods, and to interpret them in the context of national socioeconomic changes over time and the possible implications for future prevention in South-Eastern European postcommunist countries with high mortality rates. We used the Croatian National Cancer Registry data to analyse incidence trends of malignant melanoma of the skin (ICD-9 code 172 and ICD-10 code C43) in men and women aged 25-79 years by age-period-cohort modelling...
October 2017: Melanoma Research
https://www.readbyqxmd.com/read/28800031/risk-factors-for-development-of-melanoma-brain-metastasis-and-disease-progression-a-single-center-retrospective-analysis
#20
Laura J Gardner, Morgan Ward, Robert H I Andtbacka, Kenneth M Boucher, Glen M Bowen, Tawnya L Bowles, Adam L Cohen, Kenneth Grossmann, Ying J Hitchcock, Sheri L Holmen, John Hyngstrom, Hung Khong, Martin McMahon, Marcus M Monroe, Carolyn B Ross, Gita Suneja, David Wada, Douglas Grossman
Melanoma metastasis to the brain is associated with a poor prognosis. We sought to determine patient demographics and primary tumor factors associated with the development of brain metastasis (BM) and survival. We also investigated whether the BM detection setting (routine screening vs. symptomatic presentation) affected clinical outcomes. A database of melanoma patients seen from 1999 to 2015 at our institution was reviewed to identify patients who developed BM. Patients with BM were matched by initial stage with patients who did not develop BM as a control group...
October 2017: Melanoma Research
journal
journal
30785
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"